Clinical Trials Browser

Not yet recruiting × Focal Cortical Dysplasia × 90 days × Clear all

NCT07287202 2025-12-23

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Phase 1/2 Not yet recruiting

Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly